The dietary compound luteolin inhibits pancreatic cancer growth by targeting BCL-2
Z Li, Y Zhang, L Chen, H Li - Food & function, 2018 - pubs.rsc.org
Overexpression of the prosurvival protein BCL-2 contributes to malignant cell initiation,
progression and resistance to treatment. Agents that function as its natural antagonists
targeting BCL-2 must provide therapeutic benefit. In SW1990 pancreatic cancer cells,
amplified BCL-2 was observed, which was believed to offer advantages for malignant cell
survival and lead to poor patient outcome. Using structure-based virtual ligand screening,
luteolin was found to be a natural small-molecule inhibitor of BCL-2, which exhibited dose …
progression and resistance to treatment. Agents that function as its natural antagonists
targeting BCL-2 must provide therapeutic benefit. In SW1990 pancreatic cancer cells,
amplified BCL-2 was observed, which was believed to offer advantages for malignant cell
survival and lead to poor patient outcome. Using structure-based virtual ligand screening,
luteolin was found to be a natural small-molecule inhibitor of BCL-2, which exhibited dose …
The dietary compound luteolin inhibits pancreatic cancer growth by targeting BCL-2.
LZM Li ZhiMei, ZYY Zhang YiYuan, CLX Chen LiXia… - 2018 - cabidigitallibrary.org
Overexpression of the prosurvival protein BCL-2 contributes to malignant cell initiation,
progression and resistance to treatment. Agents that function as its natural antagonists
targeting BCL-2 must provide therapeutic benefit. In SW1990 pancreatic cancer cells,
amplified BCL-2 was observed, which was believed to offer advantages for malignant cell
survival and lead to poor patient outcome. Using structure-based virtual ligand screening,
luteolin was found to be a natural small-molecule inhibitor of BCL-2, which exhibited dose …
progression and resistance to treatment. Agents that function as its natural antagonists
targeting BCL-2 must provide therapeutic benefit. In SW1990 pancreatic cancer cells,
amplified BCL-2 was observed, which was believed to offer advantages for malignant cell
survival and lead to poor patient outcome. Using structure-based virtual ligand screening,
luteolin was found to be a natural small-molecule inhibitor of BCL-2, which exhibited dose …
以上显示的是最相近的搜索结果。 查看全部搜索结果